Jerry Leonard
Vyome Holdings Inc. has appointed Jerry Leonard chief financial officer, adding a finance executive with more than 25 years of experience as the clinical-stage biopharmaceutical company strengthens its financial operations while advancing programs targeting immuno-inflammatory and rare diseases.
Leonard assumed the role Sept. 1, 2026, succeeding Robert Dickey IV, who had served as interim chief financial officer since August 2025. Leonard will oversee Vyome’s financial operations, reporting, accounting, internal controls and related corporate governance responsibilities.
The appointment gives Nasdaq-listed Vyome an executive with experience spanning emerging public companies, global corporations and public accounting. His responsibilities will include strengthening the financial processes and controls supporting the company’s development pipeline and broader corporate strategy.
“Jerry brings a strong combination of public company financial leadership, operating discipline and experience in reporting, financial operations, and governance that we believe is particularly relevant to Vyome as we continue to build our organization,” CEO Venkat Nelabhotla said.
Leonard is the founder and CEO of ClearBridgeCFO, a financial leadership and transformation firm. He previously served as senior vice president, chief financial officer and secretary of VSee Health following its 2024 business combination.
Before that, Leonard was CFO of iDoc Virtual Telehealth Solutions and VSee Lab, adding experience with healthcare and technology companies to his broader financial background.
Earlier in his career, Leonard spent more than a decade as vice president of finance within the asset management business of Voya Financial. He also held finance leadership positions at IBM and Colgate-Palmolive.
Leonard began his career in public accounting at Arthur Andersen and PricewaterhouseCoopers. He is a Certified Public Accountant and earned an MBA from Emory University’s Goizueta Business School.
The combination of public company reporting, accounting and corporate finance experience is particularly relevant as Vyome manages the capital and governance requirements associated with operating a publicly traded clinical-stage biotechnology business. Drug development companies must balance investment in clinical programs with financial controls, regulatory reporting requirements and capital allocation decisions before their products generate commercial revenue.
Nelabhotla said Leonard’s experience will support Vyome’s efforts to strengthen financial processes and controls while maintaining disciplined execution across its development programs.
“Vyome has built a disciplined financial foundation as it continues to advance its development pipeline,” Leonard said. “I look forward to working with Vyome’s executive team, the Board and the broader team to further strengthen the Company’s financial operations, reporting, controls and governance.”
Based in Cambridge, Massachusetts, Vyome is focused primarily on clinical-stage assets for immuno-inflammatory conditions and rare diseases. The company is also building its business around what it describes as a U.S.-India innovation corridor, seeking to combine capabilities across the two markets while operating its development programs to global quality and safety standards.
Leonard’s appointment comes as Vyome continues building the corporate infrastructure around those programs. His mandate covers both the core accounting and reporting functions required of a Nasdaq-listed company and the financial discipline needed to support clinical development and organizational growth.
The transition also concludes Dickey’s roughly year-long tenure as interim CFO. With Leonard now in the permanent position, Vyome is adding a finance leader whose background includes public-company operations, healthcare businesses, asset management, multinational corporations and public accounting.
As Vyome advances its clinical-stage portfolio, Leonard will be responsible for aligning its financial reporting, internal controls and governance infrastructure with the company’s development and strategic priorities.